Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

DHPS-dependent hypusination of eIF5A1/2 is necessary for TGFβ/fibronectin-induced breast cancer metastasis and associates with prognostically unfavorable genomic alterations in TP53.

Güth R, Adamian Y, Geller C, Molnar J, Maddela J, Kutscher L, Bhakta K, Meade K, Kim SL, Agajanian M, Kelber JA.

Biochem Biophys Res Commun. 2019 Sep 24. pii: S0006-291X(19)31802-9. doi: 10.1016/j.bbrc.2019.09.075. [Epub ahead of print]

PMID:
31558321
2.

Secretomes from metastatic breast cancer cells, enriched for a prognostically unfavorable LCN2 axis, induce anti-inflammatory MSC actions and a tumor-supportive premetastatic lung.

Meade KJ, Sanchez F, Aguayo A, Nadales N, Hamalian SG, Uhlendorf TL, Banner LR, Kelber JA.

Oncotarget. 2019 Apr 30;10(32):3027-3039. doi: 10.18632/oncotarget.26903. eCollection 2019 Apr 30.

3.

Identification of myosin II as a cripto binding protein and regulator of cripto function in stem cells and tissue regeneration.

Hoover M, Runa F, Booker E, Diedrich JK, Duell E, Williams B, Arellano-Garcia C, Uhlendorf T, La Kim S, Fischer W, Moresco J, Gray PC, Kelber JA.

Biochem Biophys Res Commun. 2019 Jan 29;509(1):69-75. doi: 10.1016/j.bbrc.2018.12.059. Epub 2018 Dec 20.

PMID:
30579599
4.

Composition-Dependent Charge Transport in Boron Carbides Alloyed with Aromatics: Plasma Enhanced Chemical Vapor Deposition Aniline/Orthocarborane Films.

Oyelade A, Yost AJ, Benker N, Dong B, Knight S, Schubert M, Dowben PA, Kelber JA.

Langmuir. 2018 Oct 9;34(40):12007-12016. doi: 10.1021/acs.langmuir.8b02114. Epub 2018 Sep 26.

PMID:
30179498
5.

Tumor microenvironment heterogeneity: challenges and opportunities.

Runa F, Hamalian S, Meade K, Shisgal P, Gray PC, Kelber JA.

Curr Mol Biol Rep. 2017 Dec;3(4):218-229. doi: 10.1007/s40610-017-0073-7. Epub 2017 Oct 30.

6.

ITGA1 is a pre-malignant biomarker that promotes therapy resistance and metastatic potential in pancreatic cancer.

Gharibi A, La Kim S, Molnar J, Brambilla D, Adamian Y, Hoover M, Hong J, Lin J, Wolfenden L, Kelber JA.

Sci Rep. 2017 Aug 30;7(1):10060. doi: 10.1038/s41598-017-09946-z.

7.

Carborane-based polymers: a novel class of semiconductors with tunable properties.

Dong B, Oyelade A, Kelber JA.

Phys Chem Chem Phys. 2017 May 10;19(18):10986-10997. doi: 10.1039/c7cp00835j.

PMID:
28429005
8.

CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer.

Zoni E, Chen L, Karkampouna S, Granchi Z, Verhoef EI, La Manna F, Kelber J, Pelger RCM, Henry MD, Snaar-Jagalska E, van Leenders GJLH, Beimers L, Kloen P, Gray PC, van der Pluijm G, Kruithof-de Julio M.

Oncogene. 2017 Aug 17;36(33):4739-4749. doi: 10.1038/onc.2017.87. Epub 2017 Apr 10.

9.

eIF5A-PEAK1 Signaling Regulates YAP1/TAZ Protein Expression and Pancreatic Cancer Cell Growth.

Strnadel J, Choi S, Fujimura K, Wang H, Zhang W, Wyse M, Wright T, Gross E, Peinado C, Park HW, Bui J, Kelber J, Bouvet M, Guan KL, Klemke RL.

Cancer Res. 2017 Apr 15;77(8):1997-2007. doi: 10.1158/0008-5472.CAN-16-2594. Epub 2017 Apr 5.

10.

Nucleation of Graphene Layers on Magnetic Oxides: Co3O4(111) and Cr2O3(0001) from Theory and Experiment.

Beatty J, Cheng T, Cao Y, Driver MS, Goddard WA 3rd, Kelber JA.

J Phys Chem Lett. 2017 Jan 5;8(1):188-192. doi: 10.1021/acs.jpclett.6b02325. Epub 2016 Dec 19.

PMID:
27973856
11.

A novel method for RNA extraction from FFPE samples reveals significant differences in biomarker expression between orthotopic and subcutaneous pancreatic cancer patient-derived xenografts.

Hoover M, Adamian Y, Brown M, Maawy A, Chang A, Lee J, Gharibi A, Katz MH, Fleming J, Hoffman RM, Bouvet M, Doebler R, Kelber JA.

Oncotarget. 2017 Jan 24;8(4):5885-5894. doi: 10.18632/oncotarget.11809.

12.

Atomic Layer Epitaxy of h-BN(0001) Multilayers on Co(0001) and Molecular Beam Epitaxy Growth of Graphene on h-BN(0001)/Co(0001).

Driver MS, Beatty JD, Olanipekun O, Reid K, Rath A, Voyles PM, Kelber JA.

Langmuir. 2016 Mar 22;32(11):2601-7. doi: 10.1021/acs.langmuir.5b03653. Epub 2016 Mar 10.

PMID:
26940024
13.

Cellular and molecular aspects of pancreatic cancer.

Gharibi A, Adamian Y, Kelber JA.

Acta Histochem. 2016 Apr;118(3):305-16. doi: 10.1016/j.acthis.2016.01.009. Epub 2016 Feb 8. Review.

14.

Ascending the PEAK1 toward targeting TGFβ during cancer progression: Recent advances and future perspectives.

Runa F, Adamian Y, Kelber JA.

Cancer Cell Microenviron. 2016;3(1). pii: e1162. doi: 10.14800/ccm.1162. Epub 2016 Jan 28.

15.

Six-Coordinate Zinc Porphyrins for Template-Directed Synthesis of Spiro-Fused Nanorings.

Favereau L, Cnossen A, Kelber JB, Gong JQ, Oetterli RM, Cremers J, Herz LM, Anderson HL.

J Am Chem Soc. 2015 Nov 18;137(45):14256-9. doi: 10.1021/jacs.5b10126. Epub 2015 Nov 6.

16.

Synthesis and investigation of donor-porphyrin-acceptor triads with long-lived photo-induced charge-separate states.

Kelber JB, Panjwani NA, Wu D, Gómez-Bombarelli R, Lovett BW, Morton JJL, Anderson HL.

Chem Sci. 2015 Nov 1;6(11):6468-6481. doi: 10.1039/c5sc01830g. Epub 2015 Jul 31.

17.

Identification of a PEAK1/ZEB1 signaling axis during TGFβ/fibronectin-induced EMT in breast cancer.

Agajanian M, Runa F, Kelber JA.

Biochem Biophys Res Commun. 2015 Sep 25;465(3):606-12. doi: 10.1016/j.bbrc.2015.08.071. Epub 2015 Aug 20.

PMID:
26297948
18.

PEAK1 Acts as a Molecular Switch to Regulate Context-Dependent TGFβ Responses in Breast Cancer.

Agajanian M, Campeau A, Hoover M, Hou A, Brambilla D, Kim SL, Klemke RL, Kelber JA.

PLoS One. 2015 Aug 12;10(8):e0135748. doi: 10.1371/journal.pone.0135748. eCollection 2015.

19.

A hypusine-eIF5A-PEAK1 switch regulates the pathogenesis of pancreatic cancer.

Fujimura K, Wright T, Strnadel J, Kaushal S, Metildi C, Lowy AM, Bouvet M, Kelber JA, Klemke RL.

Cancer Res. 2014 Nov 15;74(22):6671-81. doi: 10.1158/0008-5472.CAN-14-1031. Epub 2014 Sep 26.

20.

CRIPTO/GRP78 signaling maintains fetal and adult mammary stem cells ex vivo.

Spike BT, Kelber JA, Booker E, Kalathur M, Rodewald R, Lipianskaya J, La J, He M, Wright T, Klemke R, Wahl GM, Gray PC.

Stem Cell Reports. 2014 Apr 3;2(4):427-39. doi: 10.1016/j.stemcr.2014.02.010. eCollection 2014 Apr 8.

21.

Procedures for the biochemical enrichment and proteomic analysis of the cytoskeletome.

Choi S, Kelber J, Jiang X, Strnadel J, Fujimura K, Pasillas M, Coppinger J, Klemke R.

Anal Biochem. 2014 Feb 1;446:102-7. doi: 10.1016/j.ab.2013.10.025. Epub 2013 Oct 22.

22.

Graphene mediated domain formation in exchange coupled graphene/Co3O4(111)/Co(0001) trilayers.

Wang Y, Kong L, Pasquale FL, Cao Y, Dong B, Tanabe I, Binek C, Dowben PA, Kelber JA.

J Phys Condens Matter. 2013 Nov 27;25(47):472203. doi: 10.1088/0953-8984/25/47/472203. Epub 2013 Oct 24.

PMID:
24154506
23.

Plasma-enhanced chemical vapor deposition of ortho-carborane: structural insights and interaction with Cu overlayers.

James R, Pasquale FL, Kelber JA.

J Phys Condens Matter. 2013 Sep 4;25(35):355004. doi: 10.1088/0953-8984/25/35/355004. Epub 2013 Jul 25.

PMID:
23883590
24.

Proteomic and biochemical methods to study the cytoskeletome.

Klemke RL, Jiang X, Choi S, Kelber JA.

Methods Mol Biol. 2013;1046:203-18. doi: 10.1007/978-1-62703-538-5_12.

25.

Novel alloy polymers formed from ortho-carborane and benzene or pyridine.

Pasquale FL, Li Y, Du J, Kelber JA.

J Phys Condens Matter. 2013 Mar 13;25(10):105801. doi: 10.1088/0953-8984/25/10/105801. Epub 2013 Feb 6.

PMID:
23388821
26.

Role of connexins in metastatic breast cancer and melanoma brain colonization.

Stoletov K, Strnadel J, Zardouzian E, Momiyama M, Park FD, Kelber JA, Pizzo DP, Hoffman R, VandenBerg SR, Klemke RL.

J Cell Sci. 2013 Feb 15;126(Pt 4):904-13. doi: 10.1242/jcs.112748. Epub 2013 Jan 15.

27.

Cancer cell migration within 3D layer-by-layer microfabricated photocrosslinked PEG scaffolds with tunable stiffness.

Soman P, Kelber JA, Lee JW, Wright TN, Vecchio KS, Klemke RL, Chen S.

Biomaterials. 2012 Oct;33(29):7064-70. doi: 10.1016/j.biomaterials.2012.06.012. Epub 2012 Jul 16.

28.

KRas induces a Src/PEAK1/ErbB2 kinase amplification loop that drives metastatic growth and therapy resistance in pancreatic cancer.

Kelber JA, Reno T, Kaushal S, Metildi C, Wright T, Stoletov K, Weems JM, Park FD, Mose E, Wang Y, Hoffman RM, Lowy AM, Bouvet M, Klemke RL.

Cancer Res. 2012 May 15;72(10):2554-64. doi: 10.1158/0008-5472.CAN-11-3552.

29.

Distorted arene core allows room-temperature columnar liquid-crystal glass with minimal side chains.

Kelber J, Achard MF, Durola F, Bock H.

Angew Chem Int Ed Engl. 2012 May 21;51(21):5200-3. doi: 10.1002/anie.201108886. Epub 2012 Apr 12. No abstract available.

PMID:
22499539
30.

Direct graphene growth on Co3O4(111) by molecular beam epitaxy.

Zhou M, Pasquale FL, Dowben PA, Boosalis A, Schubert M, Darakchieva V, Yakimova R, Kong L, Kelber JA.

J Phys Condens Matter. 2012 Feb 22;24(7):072201. doi: 10.1088/0953-8984/24/7/072201. Epub 2012 Jan 6.

PMID:
22223630
31.

Designer TGFβ superfamily ligands with diversified functionality.

Allendorph GP, Read JD, Kawakami Y, Kelber JA, Isaacs MJ, Choe S.

PLoS One. 2011;6(11):e26402. doi: 10.1371/journal.pone.0026402. Epub 2011 Nov 4.

32.
33.

Direct graphene growth on MgO: origin of the band gap.

Gaddam S, Bjelkevig C, Ge S, Fukutani K, Dowben PA, Kelber JA.

J Phys Condens Matter. 2011 Feb 23;23(7):072204. doi: 10.1088/0953-8984/23/7/072204. Epub 2011 Feb 1.

PMID:
21411874
34.

Electronic structure of a graphene/hexagonal-BN heterostructure grown on Ru(0001) by chemical vapor deposition and atomic layer deposition: extrinsically doped graphene.

Bjelkevig C, Mi Z, Xiao J, Dowben PA, Wang L, Mei WN, Kelber JA.

J Phys Condens Matter. 2010 Aug 4;22(30):302002. doi: 10.1088/0953-8984/22/30/302002. Epub 2010 Jul 2.

PMID:
21399331
35.

PEAK1, a novel kinase target in the fight against cancer.

Kelber JA, Klemke RL.

Oncotarget. 2010 Jul;1(3):219-23. No abstract available.

36.

Photofragmentation of the closo-carboranes part II: VUV assisted dehydrogenation in the closo-carboranes and semiconducting B10C2H(x) films.

Rühl E, Riehs NF, Behera S, Wilks J, Liu J, Jochims HW, Caruso AN, Boag NM, Kelber JA, Dowben PA.

J Phys Chem A. 2010 Jul 15;114(27):7284-91. doi: 10.1021/jp103805r.

PMID:
20568797
37.

Pseudopodium-enriched atypical kinase 1 regulates the cytoskeleton and cancer progression [corrected].

Wang Y, Kelber JA, Tran Cao HS, Cantin GT, Lin R, Wang W, Kaushal S, Bristow JM, Edgington TS, Hoffman RM, Bouvet M, Yates JR 3rd, Klemke RL.

Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):10920-5. doi: 10.1073/pnas.0914776107. Epub 2010 Jun 1. Erratum in: Proc Natl Acad Sci U S A. 2010 Jul 27;107(30):13556.

38.

Visualizing extravasation dynamics of metastatic tumor cells.

Stoletov K, Kato H, Zardouzian E, Kelber J, Yang J, Shattil S, Klemke R.

J Cell Sci. 2010 Jul 1;123(Pt 13):2332-41. doi: 10.1242/jcs.069443. Epub 2010 Jun 8.

39.

Blockade of Cripto binding to cell surface GRP78 inhibits oncogenic Cripto signaling via MAPK/PI3K and Smad2/3 pathways.

Kelber JA, Panopoulos AD, Shani G, Booker EC, Belmonte JC, Vale WW, Gray PC.

Oncogene. 2009 Jun 18;28(24):2324-36. doi: 10.1038/onc.2009.97. Epub 2009 May 4.

40.

Cripto is a noncompetitive activin antagonist that forms analogous signaling complexes with activin and nodal.

Kelber JA, Shani G, Booker EC, Vale WW, Gray PC.

J Biol Chem. 2008 Feb 22;283(8):4490-500. Epub 2007 Dec 18.

41.

GRP78 and Cripto form a complex at the cell surface and collaborate to inhibit transforming growth factor beta signaling and enhance cell growth.

Shani G, Fischer WH, Justice NJ, Kelber JA, Vale W, Gray PC.

Mol Cell Biol. 2008 Jan;28(2):666-77. Epub 2007 Nov 8.

42.

Cripto binds transforming growth factor beta (TGF-beta) and inhibits TGF-beta signaling.

Gray PC, Shani G, Aung K, Kelber J, Vale W.

Mol Cell Biol. 2006 Dec;26(24):9268-78. Epub 2006 Oct 9. Erratum in: Mol Cell Biol. 2008 Dec;28(23):7260.

43.

Phenotypic and genetic heterogeneity in a genome-wide linkage study of asthma families.

Altmüller J, Seidel C, Lee YA, Loesgen S, Bulle D, Friedrichs F, Jellouschek H, Kelber J, Keller A, Schuster A, Silbermann M, Wahlen W, Wolff P, Schlenvoigt G, Rüschendorf F, Nürnberg P, Wjst M.

BMC Pulm Med. 2005 Jan 5;5:1.

44.

A controlled trial of the early treatment of secondary hyperparathyroidism with calcitriol in hemodialysis patients.

Delmez JA, Kelber J, Norwood KY, Giles KS, Slatopolsky E.

Clin Nephrol. 2000 Oct;54(4):301-8.

PMID:
11076106
45.

Magnesium carbonate as a phosphorus binder: a prospective, controlled, crossover study.

Delmez JA, Kelber J, Norword KY, Giles KS, Slatopolsky E.

Kidney Int. 1996 Jan;49(1):163-7.

46.

Physiologic mechanisms of action of lovastatin in nephrotic syndrome.

Aguilar-Salinas CA, Barrett PH, Kelber J, Delmez J, Schonfeld G.

J Lipid Res. 1995 Jan;36(1):188-99.

47.

Acute effects of different concentrations of dialysate magnesium during high-efficiency dialysis.

Kelber J, Slatopolsky E, Delmez JA.

Am J Kidney Dis. 1994 Sep;24(3):453-60.

PMID:
8079970
48.

Factors affecting delivery of high-efficiency dialysis using temporary vascular access.

Kelber J, Delmez JA, Windus DW.

Am J Kidney Dis. 1993 Jul;22(1):24-9.

PMID:
8322789
49.

Effects of calcitriol and non-calcemic vitamin D analogs on secondary hyperparathyroidism.

Slatopolsky E, Berkoben M, Kelber J, Brown A, Delmez J.

Kidney Int Suppl. 1992 Oct;38:S43-9. Review. No abstract available.

PMID:
1405381

Supplemental Content

Loading ...
Support Center